In recent years, psycho-oncology has moved from a predominantly focused field on the psychological consequences of cancer to a broader approach that also considers the interaction between psychological, neurological, hormonal, immune, and tumor biology processes. In this framework, the brain-immunity-tumor axis is considered as one of the important models for explaining the two-way relationship between the patient's psychological experience and the biological processes of cancer. According to this view, the brain can influence the activity of the immune system and the tumor environment through the autonomic nervous system, the pituitary-adrenal axis, and the neurohormonal messengers , and in contrast, the messages caused by inflammation and immune activity also affect the brain and the patient's psychological experience through neural and molecular pathways. Therefore, cancer cannot be considered merely a collection of proliferating cells, but the tumor is located in a complex environment where cancer cells, immune cells, vascular network, connective tissue, inflammatory messengers, and neural pathways interact with each other continuously.
Chronic stress is one of the most important psychological variables considered in this model. Self-diagnosis of cancer can be seen as a severe threatening event, and the patient may then also face a series of ongoing stressors, such as waiting for the results of tests, surgery, chemotherapy, radiation therapy, pain, physical changes, financial problems, disruption in family roles, worry about the future, and fear of recurrence. When these stresses are prolonged, the physiological systems of the stress response remain active in a frequent or sustained form. Under normal conditions, the stress response is designed to deal with a short-term threat, but its persistence can affect the regulatory balance of neuronal, endocrinal, and immune networks.
Among these, the sympathetic nervous system has a special place. The activation of this system in response to a threat is associated with increased release of noradrenaline and adrenaline. These messengers not only regulate cardiac function, vascular and metabolism, but can also affect immune cells and certain components of the tumor environment through adrenergic receptors. In situations of chronic stress, repeated stimulation of sympathetic pathways can alter the pattern of messaging between the nervous system and peripheral tissues. This connection is important for understanding cancer biology, as many cells in the tumor environment have receptors that can respond to nerve messages.
The tumor environment or tumor microenvironment is a dynamic structure made up of cancer cells, immune cells, fibroblasts, endothelial cells, messenger molecules, and extracellular matrix. The growth and spread of the tumor depends on the interaction between these components. In such an environment, messages from the activity of the sympathetic nervous system can be associated with some pathways related to inflammation, angiogenesis, cell migration, and tissue rearrangement. The importance of this issue in psycho-oncology is that it shows that psychological and social factors can affect a part of the patient's physiological environment through specific biological pathways, although this relationship does not mean that psychological stress alone is the cause of cancer or a definite factor in its progression.
One of the important links in the brain-immune-tumor axis is inflammation. Inflammation is an essential part of the body's natural response to injury and threat, but persistent and unregulated inflammation can play a role in some stages of cancer biology. Inflammatory cells and cytokines can influence processes such as cell proliferation, tissue regeneration, angiogenesis, cell migration, and the interaction between the tumor and the immune system. As a result, the inflammatory environment can create different conditions for the growth and survival of tumor cells. On the other hand, the tumor itself canalso activate a network of immune responses by generating inflammatory signals, suggesting a two-way relationship between cancer and inflammation.
The immune system has a dual and very complex role in this. On the one hand, immune cells can recognize abnormal cells and participate in tumor control, and on the other hand, in the tumor environment some cell populations and regulatory pathways can weaken the anti-tumor immune response. Natural killer cells, T lymphocytes, dendritic cells, macrophages, and other immune components are involved in the tumor. Chronic stress and neurohormonal changes may affect the function of some of these cells, thereby altering the balance between antitumor immunity and immunosuppressive mechanisms. However, the severity and direction of these effects depend on the type of cancer, the stage of the disease, individual characteristics, treatment status, and physiological conditions.
Along with the sympathetic nervous system, the pituitary-adrenal axis is also important in regulating the stress response. The activation of this axis is associated with an increase in cortisol, and cortisol plays an important role in regulating metabolism and inflammatory responses under normal conditions. The main problem arises when the regulation of this system is affected by long-term stress. Changes in the rhythm and pattern of cortisol response can be associated with functional changes in the immune system. Therefore, in the brain-immunotumor model, the HPA axis and the sympathetic nervous system should be considered as two related and not completely separate pathways through which the psychological experience can communicate with the physiological processes of the body.
One of the important consequences of chronic stress is the development of an allostatic load or cumulative pressure caused by the repeated activation of the body's adaptive systems. A patient with cancer may experience pain, fatigue, sleep disturbances, decreased physical activity, nutritional changes, and complications of treatment at the same time as psychological stress. The combination of these factors can create significant physiological stress. In such a situation, a purely psychological or purely medical assessment cannot explain the full complexity of the patient's condition, and the biopsychosocial approach becomes more important.
Sleep disturbances are one of the factors that can strengthen the link between stress, the nervous system, and inflammation. Anxiety and worry about illness may interfere with sleep, and insufficient sleep can also reduce emotional regulation and stress tolerance. On the other hand, sleep disorders are associated with changes in hormonal regulation, autonomic nervous system activity, and certain inflammatory processes. Therefore, sleep in cancer patients should not be considered merely a side effect, but can be an important component of integrated care.
In the same vein, cancer-related fatigue is also an example of a multi-level interaction between the mind, brain, immune system, and body. Fatigue can be affected by the disease itself, treatment, anemia, pain, sleep disturbances, mood swings, and inflammatory processes. If the patient reduces their activity due to fatigue, social isolation and feelings of helplessness increase, anxiety and depression are exacerbated, and sleep is disrupted, a vicious cycle is formed that can reduce the quality of life. Psycho-oncology can reduce some of this burden by identifying these cycles and designing multidimensional interventions.
From a therapeutic perspective, the importance of the brain–immune–tumor axis does not mean that psychological interventions should be introduced as a direct treatment of cancer. The main role of psychooncological interventions is to reduce psychological distress, strengthen adaptation, improve sleep quality, enhance coping skills, regulate emotion, promote social support, and help the patient maintain a sense of meaning and control in difficult situations. Cognitive-behavioral interventions, mindfulness, relaxation, acceptance and commitment therapy, meaning-based interventions, and stress management programs can be tailored to the patient's circumstances. Stress reduction is considered here as a component of supportive care, not a substitute for medical or anti-tumor treatment.
One of the important applications of this model is to pay more attention to systematic screening for distress . Patients with high levels of psychological distress may need specialized support for anxiety, depression, sleep disturbances, communication problems, fear of relapse, or adjustment problems. Identifying these problems at different stages of the disease can help the treatment team initiate appropriate interventions sooner. In this approach, the goal is not just to reduce an anxiety score, but to identify a set of psychological and behavioral factors that can affect the experience of illness and quality of life.
On the other hand, social support can be an important moderating factor. Patients who have appropriate family and social support may have more resources to cope with the stress of treatment. Social support can reduce stress by reducing feelings of loneliness, increasing feelings of security, facilitating access to services, and assisting in managing daily affairs. However, the quality of support is more important than just the number of social relationships; excessive or controlling support may also reduce the patient's sense of independence. Therefore, psycho-oncological interventions should also assess the type and quality of social support.
Despite the scientific appeal of the brain-immune-tumor axis, the interpretation of the findings in this area should be done carefully. The relationship between stress and cancer is complex and multifactorial, and it cannot be claimed based on the available evidence that chronic stress alone causes cancer progression. Many studies in this area are faced with differences in the type of cancer, stage of the disease, treatment, age, physical condition, medications taken, and biomarkers. Also, some human studies show correlational relationships and it is not possible to draw a definitive cause-and-effect relationship from a correlational relationship. Therefore, the use of the brain-immune-tumor axis concept requires avoiding simplification and over-interpretation of the results.
In future research, the use of longitudinal schemas could be of great importance. Patient observation from diagnosis to active treatment, post-treatment period, and follow-up phase can determine how changes in stress, sleep, autonomic nervous system activity, inflammatory markers, and psychological status change with each other over time. The use of indicators such as heart rate variability, sleep patterns, cortisol, inflammatory markers, and standard Distress assessments can also allow for a more accurate study of this axis. In the future, combining biological and psychological data with digital data and wearable technologies could also help create dynamic models of patient condition monitoring.
Another important path is the development of personalized models in psycho-oncology. Not all cancer patients respond to stress in the same way, and a psychological factor may have a different effect on one person than another. Therefore, assessing individual characteristics, coping style, emotion regulation, sleep, social support, economic status, type of cancer, stage of treatment, and distress severity can help choose the appropriate intervention. In such a model, psycho-oncology moves from a general approach to more rigorous and person-centered care.
The brain-immune-tumor axis is one of the important frameworks for understanding the relationship between psychological experience and cancer biology. Chronic stress can interact with the tumor environment through increased activity of the sympathetic nervous system, changes in the HPA axis, hormonal messengers, sleep disturbances, and modulation of inflammatory and immune pathways. Inflammation can also be placed in a two-way cycle between the immune system, the brain, and the tumor, affecting the experience of symptoms and certain biological processes associated with cancer. However, this network is much more complex than a straight and linear pathway, and the progression of cancer cannot be attributed to the patient's mental state. The main value of this model in psycho-oncology is that it highlights the need for an integrated view of the patient, in which mental health, stress regulation, sleep, social support, and quality of life are taken into account alongside medical treatments. The future of psycho-oncology in this field can move towards models that combine psychological, neurological, hormonal, safety, and clinical data to provide a more accurate picture of the patient's condition and allow for early, personalized, and evidence-based interventions.